OncLive TV

Alanna K. Rahm, PhD, MS, discusses the challenges of implementing alternative delivery models for genetic counseling in prostate cancer.

Sonali M. Smith, MD, discusses frontline treatment options in mantle cell lymphoma.

Hope S. Rugo, MD, discusses takeaways from the phase 3 IMpassion130 trial in metastatic triple-negative breast cancer.

Lloyd B. Gayle, MD, discusses current treatment options for patients who develop breast implant–associated anaplastic large cell lymphoma (ALCL).

Jiaxin (Jason) Niu, MD, PhD, discusses combining immunotherapy with VEGF Inhibitors in extensive-stage small cell lung cancer.

Prapti Patel, MD, discusses the clinical implications of the FDA approval of luspatercept-aamt in myelodysplastic syndrome.

David P. Carbone, MD, PhD, discusses the importance of personalizing immunotherapy for patients with non–small cell lung cancer.

Andre Goy, MD, MS, discusses the evolution of treatment selection in mantle cell lymphoma.

James N. Gerson, MD, discusses clinical trial accrual in mantle cell lymphoma.

Elisabeth I. Heath, MD, FACP, discusses developments in nonmetastatic castration-resistant prostate cancer (CRPC).

Jonathan C. Trent, MD, PhD, sheds light on the impact of COVID-19 on the treatment of rare cancers.

Marc J. Braunstein, MD, PhD, discusses updated results from the GRIFFIN trial in multiple myeloma.

John P. Sfakianos, MD, discusses the importance of restaging transurethral resection of bladder tumors.

John P. Sfakianos, MD, discusses the importance of restaging transurethral resection of bladder tumors.

Prapti Patel, MD, discusses the clinical implications of the FDA approval of luspatercept-aamt in myelodysplastic syndrome.

Andre Goy, MD, MS, discusses the evolution of treatment selection in mantle cell lymphoma.

James N. Gerson, MD, discusses clinical trial accrual in mantle cell lymphoma.

Marc J. Braunstein, MD, PhD, discusses updated results from the GRIFFIN trial in multiple myeloma.

Elisabeth I. Heath, MD, FACP, discusses developments in nonmetastatic castration-resistant prostate cancer (CRPC).

Jonathan C. Trent, MD, PhD, sheds light on the impact of COVID-19 on the treatment of rare cancers.

Andre Goy, MD, MS, discusses research efforts with BTK inhibitors in mantle cell lymphoma.

Sonali M. Smith, MD, discusses the different safety profiles of BTK inhibitors in mantle cell lymphoma.

Shannon N. Westin, MD, MPH, discusses novel targets in endometrial cancer.

Stephen J. Freedland, MD, discusses remaining questions with the real-world utility of enzalutamide in prostate cancer.

Larry Anderson, MD, PhD, discusses recent advances made with novel therapies in multiple myeloma.

Chung-Han Lee, MD, PhD, discusses second-line treatment options in renal cell carcinoma.

Brandon G. Smaglo, MD, FACP, discusses novel therapies in advanced gastric cancer.

Andre Goy, MD, MS, discusses research efforts with BTK inhibitors in mantle cell lymphoma.

Sonali M. Smith, MD, discusses the different safety profiles of BTK inhibitors in mantle cell lymphoma.

Michael Wang, MD, discusses the utility of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.